CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,182,371 | -12.8% | 92,143 | +7.9% | 0.19% | -11.2% |
| Q2 2023 | $4,796,321 | +37.1% | 85,435 | +10.4% | 0.22% | +21.5% |
| Q1 2023 | $3,499,536 | +47.1% | 77,372 | +32.2% | 0.18% | +6.0% |
| Q4 2022 | $2,378,716 | -27.1% | 58,517 | +17.3% | 0.17% | -36.5% |
| Q3 2022 | $3,261,000 | +71.5% | 49,897 | +59.5% | 0.26% | +73.0% |
| Q2 2022 | $1,901,000 | +25.2% | 31,279 | +29.3% | 0.15% | +102.7% |
| Q1 2022 | $1,518,000 | -0.7% | 24,189 | +20.0% | 0.08% | +2.7% |
| Q4 2021 | $1,528,000 | +247.3% | 20,162 | +413.3% | 0.07% | +87.2% |
| Q3 2021 | $440,000 | -35.3% | 3,928 | -6.5% | 0.04% | -33.9% |
| Q2 2021 | $680,000 | -6.5% | 4,202 | -29.6% | 0.06% | -14.5% |
| Q1 2021 | $727,000 | -53.2% | 5,968 | -41.2% | 0.07% | -57.4% |
| Q4 2020 | $1,553,000 | +95.8% | 10,143 | +6.9% | 0.16% | +67.0% |
| Q3 2020 | $793,000 | – | 9,485 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |